

652 increases human peripheral blood-derived mast cell generation of PGD₂ in vitro at 6 hours compared to IL-33
653 alone. A, B, Data are displayed for individual experiments with cells from three different donors; differences are
654 not statistically significant.

655
656 **FIG E1.** COX-1 and COX-2 mRNA expression in mast cells and eosinophils. **A, B,** COX-1 and COX-2 mRNA
657 expression in sorted nasal polyp mast cells (**A**) and eosinophils (**B**) in subjects with AERD and CRS. A, B,
658 Data are shown as individual points with group median as measured by Mann-Whitney test.

659
660 **FIG E2.** Confirmation of TSLP protein in nasal polyp samples measured by Western blotting. Top panel, 10
661 kDa TSLP protein measured in nasal polyp lysate and 15 kDa TSLP protein measured from recombinant TSLP
662 (Novus antibody). Middle panel: Same Western blot post blocking with immunogenic peptide (Novus) plus
663 Novus antibody. Bottom panel: Same Western blot using Millipore antibody to identify TSLP.

664
665 **FIG E3.** Multiple TSLP protein bands (15 kDa and 10 kDa) expressed in nasal polyp lysates from patients with
666 AERD and CRS.


667
668 **FIG E4.** TSLP mRNA expression in sorted nasal polyp structural cells. **A, B,** Cytofluorographic detections of
669 epithelial cells and fibroblasts (**A**) and endothelial cells (**B**). **C,** TSLP mRNA expression from sorted nasal polyp
670 epithelial cells, endothelial cells, and fibroblasts.


671
672 **FIG E5.** Evaluation of arachidonic acid pathway products following in vitro stimulation of human cord blood-
673 derived mast cells with TSLP **A,** TSLP (10 ng/mL) increases mast cell generation of TXB₂ in vitro at 6 hours. **B,**
674 TSLP (10 ng/mL) stimulation does not increase mast cell generation of cysLTs at 6 hours. A, B, Data are
675 displayed for individual experiments with cells from three different donors.



676

677

678





A**B****C**